JZJunjia Zeng

Junjia Zeng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junjia Zeng has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Lingwan Hao

    School of Chemistry and Pharmaceutical Engineering Medical Science and Technology Innovation Center Shandong First Medical University & Shandong Academy of Medical Sciences Jinan Shandong China

    1 shared publication
  • Lu Zhou

    Centre for Engineering Research, School of Physics, Engineering and Computer Science, University of Hertfordshire, Hatfield AL10 9AB, UK

    1 shared publication
  • Mengzhen Wang

    Eye Institute of Shandong First Medical University Eye Hospital of Shandong First Medical University (Shandong Eye Hospital) Jinan Shandong China

    1 shared publication
  • Qinxian Ma

    Eye Institute of Shandong First Medical University Eye Hospital of Shandong First Medical University (Shandong Eye Hospital) Jinan Shandong China

    1 shared publication
  • Ruixiao Wang

    Eye Institute of Shandong First Medical University Eye Hospital of Shandong First Medical University (Shandong Eye Hospital) Jinan Shandong China

    1 shared publication
  • Rujian Jiang

    School of Chemistry and Pharmaceutical Engineering Shandong First Medical University & Shandong Academy of Medical Sciences Taian China

    1 shared publication

Latest Publications

  • Open Access

    Self‐Reinforced DNase‐Based Nanosystem With Accelerated Biofilm Disruption and Boosted Antibiotic Delivery for Bacterial Keratitis Therapy

    by Ruixiao Wang, Yan Song, Junjia Zeng, Qinxian Ma, Lu Zhou, Shuo Du, Mengzhen Wang, Lingwan Hao, Rujian Jiang, Xiaolin Qi

    Biofilm‐associated infections remain refractory to antibiotics due to the extracellular polymeric substance (EPS) barrier limiting drug penetration and promoting drug resistance genes transfer. Deoxyribonuclease I (DNase I)‐based strategies designed to degrade the EPS scaffold paradoxically fail within the biofilm microenvironment, where oxidative stress rapidly deactivates the enzyme and its cleavage efficiency remains intrinsically low. Here, we developed a self‐reinforced nanosystem (D‐HIC) by integrating MnO 2 (HMnO 2 ) with DNase I and co‐loading indocyanine green and ciprofloxacin, simultaneously addressing the intrinsic limitations of enzyme‐based therapies. Crucially, HMnO 2 catalyzed the excess ROS to protect DNase I from oxidative degradation, and this catalytic process is accompanied by the generation of Mn 2+ which was found to significantly accelerate DNase I‐mediated EPS cleavage by nearly fourfold to achieve rapid biofilm skeleton disruption. This potentiation created rapid penetration channels, enabling deep delivery of loadings for near‐infrared‐triggered complete biofilm elimination and remarkable bacterial killing rate (>99%) at reduced antibiotic doses. In a murine bacterial keratitis model, this strategy achieved superior therapeutic outcomes compared to clinical eye drops. By coupling oxidative stress relief with catalytic cofactor generation from a single material platform, this work establishes a versatile strategy that overcomes the fundamental limitations of traditional enzyme‐based antibiofilm approaches.